Abstract
Introduction: Salivary gland cancers (SGCs) are a rare and heterogeneous group of malignant tumors arising from either major or minor salivary glands. Among SGCs patients, adenoid cystic carcinoma (ACC) is the most frequent histotype and its genetic aberrations are well known even though they are generally uncommon. Non-ACC subtypes are rarer and more heterogeneous than ACC from a histological and genomic point of view. In non-ACC, some altered molecular pathways [e.g. BRAF or RET mutations, Androgen Receptor (AR)] are potentially targetable with specific drugs. Areas covered: A literature search was performed to summarize the main druggable genomic aberrations involving non-ACC SGCs. An overview of the genomics of non-ACC salivary gland malignancies is discussed. We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype. Expert opinion/commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 435-443 |
| Number of pages | 9 |
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 28 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 4 2019 |
Fingerprint
Keywords
- druggable
- genomics
- MASCC
- salivary duct carcinoma
- Salivary gland cancer
- targeted therapy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Genomics in non-adenoid cystic group of salivary gland cancers : one or more druggable entities? / Cavalieri, Stefano; Platini, Francesca; Bergamini, Cristiana; Resteghini, Carlo; Galbiati, Donata; Bossi, Paolo; Perrone, Federica; Tamborini, Elena; Quattrone, Pasquale; Licitra, Lisa; Locati, Laura Deborah; Alfieri, Salvatore.
In: Expert Opinion on Investigational Drugs, Vol. 28, No. 5, 04.05.2019, p. 435-443.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Genomics in non-adenoid cystic group of salivary gland cancers
T2 - one or more druggable entities?
AU - Cavalieri, Stefano
AU - Platini, Francesca
AU - Bergamini, Cristiana
AU - Resteghini, Carlo
AU - Galbiati, Donata
AU - Bossi, Paolo
AU - Perrone, Federica
AU - Tamborini, Elena
AU - Quattrone, Pasquale
AU - Licitra, Lisa
AU - Locati, Laura Deborah
AU - Alfieri, Salvatore
PY - 2019/5/4
Y1 - 2019/5/4
N2 - Introduction: Salivary gland cancers (SGCs) are a rare and heterogeneous group of malignant tumors arising from either major or minor salivary glands. Among SGCs patients, adenoid cystic carcinoma (ACC) is the most frequent histotype and its genetic aberrations are well known even though they are generally uncommon. Non-ACC subtypes are rarer and more heterogeneous than ACC from a histological and genomic point of view. In non-ACC, some altered molecular pathways [e.g. BRAF or RET mutations, Androgen Receptor (AR)] are potentially targetable with specific drugs. Areas covered: A literature search was performed to summarize the main druggable genomic aberrations involving non-ACC SGCs. An overview of the genomics of non-ACC salivary gland malignancies is discussed. We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype. Expert opinion/commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients.
AB - Introduction: Salivary gland cancers (SGCs) are a rare and heterogeneous group of malignant tumors arising from either major or minor salivary glands. Among SGCs patients, adenoid cystic carcinoma (ACC) is the most frequent histotype and its genetic aberrations are well known even though they are generally uncommon. Non-ACC subtypes are rarer and more heterogeneous than ACC from a histological and genomic point of view. In non-ACC, some altered molecular pathways [e.g. BRAF or RET mutations, Androgen Receptor (AR)] are potentially targetable with specific drugs. Areas covered: A literature search was performed to summarize the main druggable genomic aberrations involving non-ACC SGCs. An overview of the genomics of non-ACC salivary gland malignancies is discussed. We describe the pattern of potentially targetable genomic alterations in non-ACC salivary gland malignancies according to their frequency rather than to the single non-ACC histotype. Expert opinion/commentary: The genetic profiling through in-depth molecular analyses [e.g. Next-generation sequencing (NGS)] is advised in all patients affected by recurrent and/or metastatic non-ACC SGCs to find any potentially druggable target. Some histotypes may carry driving mutations that must be investigated and defined. For the rare cancers, access to a referral center is recommended to optimize the management of these patients.
KW - druggable
KW - genomics
KW - MASCC
KW - salivary duct carcinoma
KW - Salivary gland cancer
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85065323249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065323249&partnerID=8YFLogxK
U2 - 10.1080/13543784.2019.1598376
DO - 10.1080/13543784.2019.1598376
M3 - Article
C2 - 30897975
AN - SCOPUS:85065323249
VL - 28
SP - 435
EP - 443
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 5
ER -